Prediction of Long-Term Incidence of Chronic Cardiovascular and Cardiopulmonary Diseases in Primary Care Patients for Population Health Monitoring: The Intermountain Chronic Disease Model (ICHRON).


Journal

Mayo Clinic proceedings
ISSN: 1942-5546
Titre abrégé: Mayo Clin Proc
Pays: England
ID NLM: 0405543

Informations de publication

Date de publication:
07 2019
Historique:
received: 22 03 2018
revised: 30 05 2018
accepted: 14 06 2018
pubmed: 24 12 2018
medline: 10 1 2020
entrez: 23 12 2018
Statut: ppublish

Résumé

To apply the practical parsimonious modeling method of the Intermountain Mortality Risk Score in a primary care environment to predict chronic disease (ChrD) onset. Primary care patients free of ChrD (women: n=98,711; men: n=45,543) were evaluated to develop (70% [n=95,882] of patients) and validate (the other 30% [n=48,372]) the sex-specific Intermountain Chronic Disease Risk Score (ICHRON) if seen initially between January 1, 2003, and December 31, 2005. The sex-specific ICHRON was composed of comprehensive metabolic profile and complete blood count components and age. The primary outcome was the first diagnosis of coronary artery disease, myocardial infarction, heart failure, atrial fibrillation, stroke, diabetes, renal failure, chronic obstructive pulmonary disease, peripheral vascular disease, or dementia within 3 years of baseline. At 3 years, 9.0% of men (mean age, 44±16 years) and 6.6% of women (mean age, 42±16 years) received a diagnosis of ChrD. In the derivation population, C-statistics were 0.783 (95% CI, 0.774-0.791) for men and 0.774 (95% CI, 0.767-0.781) for women. In the validation population, C-statistics were 0.774 (95% CI, 0.762-0.786) for men and 0.762 (95% CI, 0.752-0.772) for women. Evaluation of 10-year outcomes for ICHRON and analysis of its association with each outcome individually at 3 years revealed similar predictive ability. An augmented intelligence clinical decision tool for primary care, ICHRON, is developed using common laboratory parameters, which provides good discrimination of ChrD risk at 3 and 10 years.

Identifiants

pubmed: 30577973
pii: S0025-6196(18)30612-8
doi: 10.1016/j.mayocp.2018.06.029
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1221-1230

Informations de copyright

Copyright © 2018 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.

Auteurs

Heidi T May (HT)

Intermountain Medical Center Heart Institute, Salt Lake City, UT. Electronic address: heidi.may@imail.org.

Donald L Lappé (DL)

Intermountain Medical Center Heart Institute, Salt Lake City, UT.

Kirk U Knowlton (KU)

Intermountain Medical Center Heart Institute, Salt Lake City, UT; Department of Medicine, University of Utah, Salt Lake City, UT.

Joseph B Muhlestein (JB)

Intermountain Medical Center Heart Institute, Salt Lake City, UT; Department of Medicine, University of Utah, Salt Lake City, UT.

Jeffrey L Anderson (JL)

Intermountain Medical Center Heart Institute, Salt Lake City, UT; Department of Medicine, University of Utah, Salt Lake City, UT.

Benjamin D Horne (BD)

Intermountain Medical Center Heart Institute, Salt Lake City, UT; Department of Medicine, University of Utah, Salt Lake City, UT.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH